RT Journal Article
SR Electronic
A1 Rizzo, Toni
T1 Apremilast Was Associated with an Acceptable Safety Profile in ESTEEM Trials
JF MD Conference Express
YR 2014
FD SAGE Publications
VO 14
IS 37
SP 6
OP 7
DO 10.1177/155989771437002
UL http://mdc.sagepub.com/content/14/37/6.abstract
AB Two phase 3 randomized controlled trials were performed to evaluate the safety and efficacy of oral apremilast (CC-10004) in patients with moderate to severe plaque psoriasis. This article discusses the safety analysis from the pooled data of the ESTEEM 1 [NCT01194219] and ESTEEM 2 trials [NCT01232283].